SNYs Post-M-enox Approval Pricing
Healthtrust, and other GPOs, had pricing of WAC - 30% prior to M-enox approval. On the day of approval SNY came down another 1000 basis points to WAC - 40% to Healthtrust members, and as it turns out, most GPOs.
Pharmacists, like many professions, run in pretty tight groups. That's especially true for hospital pharmacists as some work part-time or as needed for other hospitals to supplement their full-time income. A colleague of mine who fits that description informs me that this 30-40% discount fact was his experience of his GPO too (that is different from Healthtrust).
I wonder if SNY can conduct a price war with what once was their best selling product if their Genzyme bid is deemed too low? Seems like their chance of acquiring Genzyme diminishes if their income takes too big a hit. Is their immediate 4% reduction projection (earnings or revenue, I can't recall?) factoring a enoxaparin price war into it?
Market Data 
Markets 
AI
